Videos
Presenter: Jonathan Norris Jon Norris is a Managing Director with SVB Healthcare team, responsible for new business development. View Full Profile
Read MorePresenter: Joseph Gilliam Mr. Gilliam has over 16 year’s experience in strategic advisory services, private and public equity and debt financings. Prior to J.P. Morgan,…
Read MorePresenter: Emmett T. Cunningham Jr., MD, PhD, MPH Dr. Cunningham joined Clarus Ventures with 20+ years in the biomedical and biopharmaceutical sectors. Prior, Dr. Cunningham…
Read MoreAllegro Ophthalmics describes itself as a “mid-stage biotech company.” Its lead agent, Luminate, is an integrin peptide therapy that is the subject of a number…
Read MoreCEO Mark Shearman, MD, PhD, describes Applied Genetic Technologies Corp., known as AGTC, as a clinical-stage biotechnology company focused on developing its proprietary gene vector…
Read MoreVision Medicines is working on developing two agents for the treatment of ocular diseases: VM100 for treatment of geographic atrophy and intermediate age-related macular degeneration…
Read MoreDavid P. Southwell, president and CEO of Inotek Pharmaceuticals, spelled out the focus of his clinical-stage biopharmaceutical firm in no uncertain terms at OIS@AAO. “Inotek…
Read MoreEleven Biotherapeutics is using its proprietary AMP-Rx protein-engineering platform to develop agents for more effective treatment of allergic conjunctivitis as well as to investigate new…
Read MorePatients with ocular melanoma have very few treatment options, and those that exist – removal of the eye or plaque radiation – leave them blind…
Read MorePresenter: Shelley Boyd, MD, FRCSC Shelley Boyd, MD, FRCSC, is an Ophthalmologist specializing in diseases of the retina and founding President & CSO of Translatum…
Read MoreOcata Therapeutics, which has trademarked the term Regenerative Ophthalmology, is developing stem cell therapies for Stargardt macular degeneration, dry age-related macular degeneration (AMD), and myopic…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")